AC Immune (IMR) Stock Overview
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IMR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AC Immune SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.06 |
| 52 Week High | US$3.32 |
| 52 Week Low | US$1.24 |
| Beta | 1.6 |
| 1 Month Change | 27.82% |
| 3 Month Change | 3.74% |
| 1 Year Change | 8.72% |
| 3 Year Change | 43.49% |
| 5 Year Change | -40.91% |
| Change since IPO | -78.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 15.3% | 3.8% | 1.8% |
| 1Y | 8.7% | -30.1% | 14.5% |
Return vs Industry: IMR exceeded the German Biotechs industry which returned -30.8% over the past year.
Return vs Market: IMR underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| IMR volatility | |
|---|---|
| IMR Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IMR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IMR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 153 | Andrea Pfeifer | www.acimmune.com |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
AC Immune SA Fundamentals Summary
| IMR fundamental statistics | |
|---|---|
| Market cap | €283.84m |
| Earnings (TTM) | -€77.44m |
| Revenue (TTM) | €4.71m |
Is IMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMR income statement (TTM) | |
|---|---|
| Revenue | CHF 4.37m |
| Cost of Revenue | CHF 61.60m |
| Gross Profit | -CHF 57.23m |
| Other Expenses | CHF 14.65m |
| Earnings | -CHF 71.87m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -1,308.92% |
| Net Profit Margin | -1,643.89% |
| Debt/Equity Ratio | 0% |
How did IMR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 17:25 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AC Immune SA is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Andrew Fein | H.C. Wainwright & Co. |
| Lucy Codrington | Jefferies LLC |